Myome introduces new genomic testing capabilities at ACMG 2026.
- Launch of Zenith portfolio
- Long-read methylation analysis
- Collaboration with Natera
Myome has unveiled its Zeninth portfolio at the ACMG 2026 meeting, featuring new genomic testing technologies. A key highlight is the introduction of long-read methylation analysis, which aims to enhance the understanding of methylation patterns in DNA. This innovative approach is expected to provide deeper insights into genomic data and improve patient outcomes.
In collaboration with Natera, a prominent player in genetic testing, Myome's new analysis method focuses on the complexities of methylation—an essential process that influences gene expression. The long-read technology can capture detailed genomic information, potentially advancing research and clinical applications. This partnership aligns with Myome’s commitment to broadening the scope of precision medicine.
The Zenith portfolio’s launch signifies a notable step in the evolution of genomic analysis, which is critical for personalized healthcare strategies. By integrating sophisticated technologies like long-read methylation analysis, Myome and Natera are well-positioned to lead in the dynamic field of genomic diagnostics.
